{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:37:22Z","timestamp":1790789842451,"version":"4.1.0"},"reference-count":24,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2016]]},"DOI":"10.5582\/irdr.2016.01024","type":"journal-article","created":{"date-parts":[[2016,8,16]],"date-time":"2016-08-16T22:07:48Z","timestamp":1471385268000},"page":"185-191","source":"Crossref","is-referenced-by-count":152,"title":["Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China"],"prefix":"10.5582","volume":"5","author":[{"given":"Xianping","family":"Lu","sequence":"first","affiliation":[{"name":"Chipscreen Biosciences Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Ning","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Li","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixiang","family":"Cao","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhao","family":"Wang","sequence":"additional","affiliation":[{"name":"Chipscreen Biosciences Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89:3909-3918.","DOI":"10.1182\/blood.V89.11.3909"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol. 2004; 15:1447-1449.","DOI":"10.1093\/annonc\/mdh409"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007; 21:201-216.","DOI":"10.1016\/j.blre.2007.03.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sun J, Yang Q, Lu Z, He M, Gao L, Zhu M, Sun L, Wei L, Li M, Liu C, Zheng J, Liu W, Li G, Chen J. Distribution of lymphoid neoplasms in China: Analysis of 4,638 cases according to the World Health Organization classification. Am J Clin Pathol. 2012; 138:429-434.","DOI":"10.1309\/AJCP7YLTQPUSDQ5C"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008; 26:4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"6","unstructured":"6. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology\u2122: Non-Hodgkin's Lymphoma, v2.2016. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf (accessed March 15, 2016)"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. O'Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-Cell lymphoma: Results from the pivotal PROPEL study. J clinOncol. 2011; 29:1182-1189.","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012; 30:631-636.","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. O'Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T-Cell lymphoma:Results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015; 33:2492-2499.","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013; 153:38-55.","DOI":"10.1016\/j.cell.2013.03.008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer. 2001; 1:194-202.","DOI":"10.1038\/35106079"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. deRuijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): Characterization of the classical HDAC family. Biochem J.2003; 370:737-749.","DOI":"10.1042\/bj20021321"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009; 277:8-21.","DOI":"10.1016\/j.canlet.2008.08.016"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy. Expert Opin Ther Targets. 2013; 17:29-41.","DOI":"10.1517\/14728222.2013.729042"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Pan DS, Yang QJ, Fu X, Shan S, Zhu JZ, Zhang K, Li ZB, Ning ZQ, Lu XP. Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment. MedChemComm. 2014, 5:1789-1796.","DOI":"10.1039\/C4MD00350K"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, Zhang J, Dong M, Du X, Lu XP. Chidamide (CS055\/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer ChemotherPharmacol. 2012; 69:901-909.","DOI":"10.1007\/s00280-011-1766-x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Gong K, Xie J, Yi H, Li W. CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012; 443:735-746.","DOI":"10.1042\/BJ20111685"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yao Y, Zhou J, Wang L, Gao X, Ning Q, Jiang M, Wang J, Wang L, Yu L. Increased PRAME-Specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine. PLoS One. 2013; 8:e70522.","DOI":"10.1371\/journal.pone.0070522"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Zhou Y, Pan DS, Shan S, Zhu JZ, Zhang K, Yue XP, Nie LP, Wan J, Lu XP, Zhang W, Ning ZQ. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomed Pharmacother. 2014; 68:483-491.","DOI":"10.1016\/j.biopha.2014.03.011"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Dong M, Ning ZQ, Xing PY, Xu JL, Cao HX, Dou GF, Meng ZY, Shi YK, Lu XP, Feng FY. Phase I study of chidamide (CS055\/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemother Pharmacol. 2012; 69:1413-1422.","DOI":"10.1007\/s00280-012-1847-5"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fournel M, Bonfils C, Hou Y, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther. 2008; 7:759-768.","DOI":"10.1158\/1535-7163.MCT-07-2026"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shi Y, Dong M, Hong X, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015; 26:1766-1771.","DOI":"10.1093\/annonc\/mdv237"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Odejide O, Weigert O, Lane AA, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood. 2014; 123:1293-1296.","DOI":"10.1182\/blood-2013-10-531509"},{"key":"24","unstructured":"24. Lu XP, Ning ZQ, Li ZB, Pan DS, Shan S, Guo X, Cao HX, Yu JD, Yang QJ. Discovery and development of HDAC subtype selective inhibitor chidamide: Potential immunomodulatory activity against cancers. In: Successful drug discovery: Vol.II (Fischer J, Childers W, eds.). Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2016; pp. 89-115."}],"container-title":["Intractable & Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/3\/5_2016.01024\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T06:15:53Z","timestamp":1601014553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/5\/3\/5_2016.01024\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2016.01024","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}